BOVILIS CLOSTRIDIAL VACCINE PORTFOLIO - Stay one step ahead of ever-present threats ...with Bovilis clostridial vaccines - Merck ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Stay one step ahead M POTENT
O
of ever-present threats
IA
FR
L
...with Bovilis®
clostridial vaccines
PE
TO
CE
RFOR MAN
BOVILIS® CLOSTRIDIAL VACCINE PORTFOLIO5 HARD FACTS ABOUT
CLOSTRIDIAL DISEASES
1. The natural habitats of clostridia (anaerobic, gram-positive organisms that are found either as living
cells or dormant spores) are soils and the intestinal tracts of animals.1
2. Pathogenic strains or their toxins may be acquired by susceptible animals, either by wound
contamination or ingestion.1
3. Clostridia thrive in wounds or tissue with little or no exposure to oxygen, causing two categories of
disease.
Diseases in which the organisms actively invade or when Diseases characterized by toxemia resulting from the
locally dormant spores are activated and reproduce in absorption of toxins produced by organisms within the
the tissues of the host, with the production of toxins that digestive system (enterotoxemias), in devitalized tissue
enhance the spread of infection (gas-gangrene group, (tetanus), or in food or carrion outside the body (botulism).1
clostridial cellulitides group).1
4. Clostridial diseases strike quickly and often fatally, making them a constant threat to successful
cattle production in many parts of the world.1
5. Vaccination provides a cost-effective and responsible way to help:
• Prevent the loss of valuable cattle.
• Decrease the need for the use of antibiotics, in keeping with marketplace trends and new Canadian
regulations regarding the prudent use of antimicrobials.5 COMPELLING REASONS TO PROTECT
VALUABLE CATTLE WITH BOVILIS® CLOSTRIDIAL
VACCINES FROM MERCK ANIMAL HEALTH
1. Extensive, flexible coverage against important clostridial pathogens.
Why include tetanus?
2. The only 8- and 9-way clostridial vaccines available in Canada that
include coverage against tetanus. Protecting cattle against
tetanus makes economic
3. An 8-way vaccine that also protects against Histophilus somnus, sense, since treatment
a bacterial pathogen commonly linked with bovine respiratory is time consuming and
disease (BRD). expensive, with mortality
rates reaching upwards
4. The patented SPUR® adjuvant, for low reactivity and to help ensure of 80% in some cases.
the precise amount of antigens required for immunization are
delivered with every dose.
5. Subcutaneous administration that helps promote beef quality.
MERCK ANIMAL HEALTH’S BOVILIS® LINE OF CLOSTRIDIAL VACCINES
Vision® 8 Vision® 8 Somnus
Covexin® Plus Tasvax® 8
with SPUR with SPUR®
9-way coverage against 8-way coverage against 8-way coverage against 8-way coverage against
clostridial diseases clostridial diseases clostridial diseases clostridial diseases
INCLUDING Tetanus INCLUDING Tetanus with patented INCLUDING Histophilus somni
SPUR® adjuvant
with patented
SPUR® adjuvant
The risk of exposure to clostridia is high. The benefits of preventive vaccination are clear.
1. Stämpfi HR. Overview of clostridial diseases. Merck Veterinary Manual. Available at https://www.merckvetmanual.com/generalized-conditions/clostridial-diseases/overview-of-clostridial-diseases (consulted July 19, 2019).
COVEXIN®, TASVAX® and VISION® are registered trademarks of Intervet International B.V. Used under license.
MERCK® is a registered trademark of Merck Canada Inc.
© 2019 Intervet Canada Corp. All rights reserved.Covexin® Plus
The only cattle vaccine that provides broad protection against
9 deadly clostridial pathogens, including tetanus
• Contains purified extracts of 9 clostridial diseases, including tetanus.
• Low-volume 2-mL dose, administered subcutaneously.
- Reduced incidence of injection-site lesions.1
• Proprietary adjuvant traps the maximum amount of antigens, for optimal safety and efficacy.Covexin® Plus at a glance
INDICATIONS
Covexin® Plus
• Healthy cattle, 3 months of age or older
BACTERIN-TOXOID
Clostridium
C. tetani (Tetanus) • Aids in the prevention of disease
C. chauvoei (Blackleg) • Aids in the prevention of disease
C. septicum (Malignant edema) • Aids in the prevention of disease
C. novyi Type B (Black disease or
• Aids in the prevention of disease
infectious necrotic hepatitis)
C. haemolyticum (Bacillary • Aids in the prevention of disease
hemoglobinuria)
C. sordellii • Aids in the prevention of disease
C. perfringens
C. perfringens Type C
• Aids in the prevention of disease
(Enterotoxemia)
C. perfringens Type D • Aids in the prevention of disease
(Enterotoxemia)
Beta and epsilon toxins of
• Aids in the prevention of disease
C. perfringens Type B*
* Although C. perfringens Type B is not a signifciant problem in Canada, immunity is derived from a combination of Type C (beta) and Type D (epsilon) C. perfringens fractions.
DOSAGE
PRIMARY VACCINATION 2 mL, subcutaneously
Administer another 2 mL dose in 3 weeks
REVACCINATION Calves vaccinated at 3 to 6 months of age should be given a third vaccination with either Covexin®
Plus or another vaccine containing C. perfringens Type D epsilon toxoid, to aid in the prevention of
disease caused by C. perfringens Type D.
Revaccinate annually with 2 mL prior to periods of extreme risk or parturition.
WITHDRAWAL PERIOD PRESENTATION
10 doses (20 mL)
21 days 50 doses (100 mL)
125 doses (250 mL)
Always read and follow the label instructions to ensure this product is suitable for the animal to be vaccinated.
Please consult the summary page for the complete line of Merck Animal Health clostridial vaccines for cattle.
1. George MH. Injection site lesions in carcasses of cattle receiving injections at branding and weaning. Journal of Animal Science (1995) 73: 3235-3240.
COVEXIN® is a registered trademark of Intervet International B.V. Used under license.
MERCK® is a registered trademark of Merck Canada Inc.
© 2019 Intervet Canada Corp. All rights reserved.Tasvax® 8 Essential 8-way coverage against ever-present and life-threatening clostridial diseases, including tetanus • Contains the immunizing antigens of 8 important clostridial pathogens, including tetanus. • Formulated with a potassium alum adjuvant.
Tasvax® 8 at a glance
INDICATIONS
Tasvax® 8 • Healthy cattle
BACTERIN-TOXOID
Clostridium
C. chauvoei (Blackleg) • For the vaccination of cattle against disease
C. haemolyticum (Bacillary • For the vaccination of cattle against disease
hemoglobinuria)
C. novyi Type B (Black disease
• For the vaccination of cattle against disease
or infectious necrotic hepatitis)
C. perfringens Type B
• For the vaccination of cattle against disease
(Lamb dysentery)
C. perfringens Type C
• For the vaccination of cattle against disease
(Hemorrhagic enterotoxemia)
C. perfringens Type D
• For the vaccination of cattle against disease
(Pulpy kidney)
C. septicum
• For the vaccination of cattle against disease
(Malignant edema)
C. tetani (Tetanus) • For the vaccination of cattle against disease
DOSAGE
PRIMARY VACCINATION Two 4-mL subcutaneous injections,
with an interval of 6 weeks between injections.
REVACCINATION To maintain a constant level of high immunity, booster injections should be administered:
• at 6-month intervals, or
• when outbreaks are seasonal, at least 2 weeks before an anticipated outbreak.
Calves vaccinated before 3 months of age should be revaccinated at 4 to 6 months of age.
Calves vaccinated at 3 months of age or older should be revaccinated 6 weeks later.
WITHDRAWAL PERIOD PRESENTATION
50 mL Flexipack
100 mL Flexipack
21 days
250 mL Flexipack
500 mL Flexipack
Always read and follow the label instructions to ensure this product is suitable for the animal to be vaccinated.
Please consult the summary page for the complete line of Merck Animal Health clostridial vaccines for cattle.
TASVAX® is a registered trademark of Intervet International B.V. Used under license.
MERCK® is a registered trademark of Merck Canada Inc.
© 2019 Intervet Canada Corp. All rights reserved.Vision® 8 with SPUR® Low-volume, low-reactive 8-way clostridial vaccine with unique advanced antigen delivery • Contains immunity-stimulating antigens of major clostridial pathogens. • Advanced antigen delivery with patented SPUR® technology. - After shaking to mix, the SPUR® adjuvant keeps antigens in suspension for long periods of time, instead of settling out. - Homogeneity helps ensure each animal receives the precise amount of antigens required for immunization in every single dose. - The SPUR® adjuvant provides more binding sites for the antigens, plus a one-of-a-kind “entrapment” feature. - Greater antigen exposure induces optimal immune response. • In comparative trials, low-volume 2-mL subcutaneous Vision® vaccines were shown to result in statistically fewer and less severe post-vaccinal injection site reactions vs. 5-mL clostridial vaccines.1
Vision® 8 with SPUR® at a glance
INDICATIONS
Vision® 8 with SPUR® • Healthy cattle
BACTERIN-TOXOID
Clostridium
C. chauvoei (Blackleg) • Aids in the prevention of disease
C. septicum (Malignant edema) • Aids in the prevention of disease
C. haemolyticum (Bacillary • Aids in the prevention of disease
hemoglobinuria/Red water)
C. novyi (Black disease) • Aids in the prevention of disease
C. sordelli • Aids in the prevention of disease
C. perfringens Type C
• Aids in the prevention of disease
(Enterotoxemia)
C. perfringens Type D
• Aids in the prevention of disease
(Enterotoxemia)
DOSAGE
PRIMARY VACCINATION 2 mL, subcutaneously
Repeat in 3 to 4 weeks
REVACCINATION In animals subject to reexposure to C. haemolyticum, revaccinate every 5 to 6 months.
WITHDRAWAL PERIOD PRESENTATION
10 doses (20 mL)
21 days
50 doses (100 mL)
Always read and follow the label instructions to ensure this product is suitable for the animal to be vaccinated.
Please consult the summary page for the complete line of Merck Animal Health clostridial vaccines for cattle.
1. George MH. Injection site lesions in carcasses of cattle receiving injections at branding and weaning. Journal of Animal Science (1995) 73: 3235-3240.
VISION® is a registered trademark of Intervet International B.V. Used under license.
MERCK® is a registered trademark of Merck Canada Inc.
© 2019 Intervet Canada Corp. All rights reserved.Vision® 8 Somnus with SPUR ®
Dual clostridial disease and haemophilosis coverage in a unique
low-volume vaccine with advanced antigen delivery
• Combination vaccine with extensive coverage against:
- Eight important clostridial pathogens, plus
- Histophilus somni, one of the three major bacterial pathogens isolated in calves with BRD.1,2
• Advanced antigen delivery with patented SPUR® technology.
- After shaking to mix, the SPUR® adjuvant keeps antigens in suspension for long periods of
time, instead of settling out.
- Homogeneity helps ensure each animal receives the precise amount of antigens
required for immunization in every single dose.
- The SPUR® adjuvant provides more binding sites for the antigens, plus a one-of-a-kind
“entrapment” feature.
- Greater antigen exposure induces optimal immune response.
• In comparative trials, low-volume 2-mL subcutaneous Vision® vaccines were shown to result
in statistically fewer and less severe post-vaccinal injection site reactions vs. 5-mL clostridial
vaccines.3Vision® 8 Somnus with SPUR® at a glance
INDICATIONS
Vision® 8 Somnus • Healthy cattle
with SPUR®
BACTERIN-TOXOID
Clostridium
C. chauvoei (Blackleg) • Aids in the prevention of disease
C. septicum (Malignant edema) • Aids in the prevention of disease
C. haemolyticum (Bacillary
hemoglobinuria) • Aids in the prevention of disease
C. novyi (Black disease) • Aids in the prevention of disease
C. sordelli • Aids in the prevention of disease
C. perfringens Type C
• Aids in the prevention of disease
(Enterotoxemia)
C. perfringens Type D
• Aids in the prevention of disease
(Enterotoxemia)
Histophilus
H. somni • Aids in the prevention of disease
DOSAGE
PRIMARY VACCINATION 2 mL, subcutaneously
Repeat in 3 to 4 weeks
REVACCINATION In animals subject to reexposure to C. haemolyticum, revaccinate every 5 to 6 months.
WITHDRAWAL PERIOD PRESENTATION
10 doses (20 mL)
21 days 50 doses (100 mL)
250 doses (500 mL)
Always read and follow the label instructions to ensure this product is suitable for the animal to be vaccinated.
Please consult the summary page for the complete line of Merck Animal Health clostridial vaccines for cattle.
1. Gagea MI, Bateman KG, et al. Diseases and pathogens associated with mortality in Ontario beef feedlots. J Vet Diagn Invest (2006) 18: 18-28.
2. Francoz D, Buczinski S, et al. Identification and determination of the antimicrobial susceptibility of the main respiratory pathogens isolated from calves in dairy herds with respiratory diseases in Québec. The AABP
Proceedings (September 2013) Vol. 46.
3. George MH. Injection site lesions in carcasses of cattle receiving injections at branding and weaning. Journal of Animal Science (1995) 73: 3235-3240.
VISION® is a registered trademark of Intervet International B.V. Used under license.
MERCK® is a registered trademark of Merck Canada Inc.
© 2019 Intervet Canada Corp. All rights reserved.Overview of Merck Animal Health’s Bovilis®
line of clostridial vaccines
The chart below provides a summary of Bovilis® vaccines that include coverage against important
clostridial pathogens, to assist veterinarians and producers in developing comprehensive vaccination
programs tailored to specific needs and herd management objectives.
Covexin® Plus Tasvax® 8 Vision® 8 with Vision® 8 Somnus
SPUR® with SPUR®
VACCINE ANTIGENS
Clostridium
C. chauvoei
C. septicum
C. haemolyticum
C. novyi
C. novyi Type B
C. sordelli
C. perfringens Type B * * *
C. perfringens Type C
C. perfringens Type D
C. tetani
Histophilus
H. somni
ADMINISTRATION
Dose volume 2 mL 4 mL 2 mL 2 mL
Administration SQ SQ SQ SQ
* Immunity is derived from a combination of Type C (beta) and Type D (epsilon) C. perfringens fractions.
Always read and follow the label instructions to ensure this product is suitable for the animal to be vaccinated.
COVEXIN®, TASVAX® and VISION® are registered trademarks of Intervet International B.V. Used under license.
MERCK® is a registered trademark of Merck Canada Inc.
© 2019 Intervet Canada Corp. All rights reserved.Frequently asked questions
WHICH CATTLE VACCINES IN THE MERCK ANIMAL HEALTH
PORTFOLIO INCLUDE CLOSTRIDIAL PROTECTION?
Merck Animal Health offers an extensive portfolio of vaccines to protect cattle against respiratory,
reproductive, clostridial and enteric pathogens.
The following vaccines include coverage against important clostridial pathogens, providing veterinarians
and producers with flexible options for customized vaccination programs in response to specific needs and
disease risks:
• Covexin® Plus • Vision® 8 with SPUR®
• Tasvax® 8 • Vision® 8 Somnus with SPUR®
To find out more about each of these products, please consult the vaccine information sheets.
WHY IS IT IMPORTANT TO VACCINATE AGAINST
CLOSTRIDIAL DISEASES?
Clostridial diseases are caused by clostridia, bacteria that are widespread in the environment and are
normally found in soils and in animals’ intestinal tracts. Clostridia spores are highly resistant and can survive
for very long periods in the environment. They may also lay dormant in the gastrointestinal tract and tissues
of healthy animals.
Disease occurs when clostridia enter the body and encounter conditions where there is little or no oxygen,
which causes them to multiply and release toxins.
Disease can appear abruptly and often fatally. Treatment success is rare.
Because clostridia are ever-present in the environment, all animals are at risk of exposure, and should be
vaccinated against clostridial diseases.
WHY IS PROTECTION AGAINST TETANUS IMPORTANT
Tetanus is caused by bacteria called Clostridium tetani that thrive in wounds or tissue with little or no
exposure to oxygen. Avoiding tetanus makes sense, since treatment is very time-consuming and expensive,
and mortality rates can exceed 80%.
As a general rule, vaccination against tetanus is recommended before periods of high risk, such as:
• Calving • Ear tagging • Abrupt changes in diet
• Potential injuries • Dehorning and/or increased
consumption
• Tail docking • Banding/castrationDO ALL 8-WAY CLOSTRIDIAL VACCINES PROVIDE
PROTECTION AGAINST TETANUS?
Contrary to popular belief, 8-way clostridial vaccines do not automatically provide coverage against
tetanus.
In Canada, only two vaccines with extensive clostridial protection include a tetanus toxoid:
• Covexin® Plus
• Tasvax® 8
AT WHAT AGE ARE ANIMALS MOST SUSCEPTIBLE TO
CLOSTRIDIAL DISEASES?
APPROXIMATE AGE OF SUSCEPTIBILITY
ANTIGEN DISEASES
0-14 days 2-13 weeks 3-12 months 1-3 years > 3 years
Clostridium chauvœi Blackleg
Red water (bacillary
Clostridium hæmolyticum
hemoglobinuria)
Black disease (infectious
Clostridium novyi (Type B) necrotic hepatitis), malignant
edema, gas gangrene
Clostridium perfringens (Type B) Enterotoxemia, enteritis
Hemorrhagic enterotoxemia,
Clostridium perfringens (Type C)
necrotic enteritis
Clostridium perfringens (Type D) Pulpy kidney (enterotoxemia)
Malignant edema, gas
Clostridium septicum
gangrene, enterotoxemia
Enterotoxemia, sudden death,
Clostridium sordellii
malignant edema
Tetanus, lock jaw, spastic
Clostridium tetani
paralysisWHAT ARE THE BENEFITS OF THE PATENTED ADJUVANT
IN VISION® 8 WITH SPUR® AND VISION® 8 SOMNUS
WITH SPUR®?
Vision® 8 with SPUR® and Vision® 8 Somnus with SPUR® are designed for low reactivity, with an advanced
antigen delivery featuring exclusive patented SPUR® technology.
The proprietary SPUR® adjuvant keeps the antigens in stable suspension for long periods of time, instead of
settling out.
These unique suspension properties provide more exposed available binding sites for the antigens, with an
“entrapment” feature not found in any other adjuvant, to help:
• Induce an optimal immune response.
• Ensure that each animal receives the precise amount of antigens required for immunization in every single dose.
In comparative trials, low-volume 2-mL subcutaneous Vision® vaccines were shown to result in statistically
fewer and less severe post-vaccinal injection site reactions vs. 5-mL clostridial vaccines.1
IN A NUTSHELL, WHAT COVERAGE DO THE VACCINES
IN MERCK ANIMAL HEALTH’S BOVILIS® CLOSTRIDIAL
PROTECTION PORTFOLIO PROVIDE?
Vision® 8 Vision® 8 Somnus
Covexin® Plus Tasvax® 8
with SPUR with SPUR®
9-way coverage against 8-way coverage against 8-way coverage against 8-way coverage against
clostridial diseases clostridial diseases clostridial diseases clostridial diseases
INCLUDING Tetanus INCLUDING Tetanus with patented PLUS Histophilus somni
SPUR® adjuvant
with patented
SPUR® adjuvant
1. George MH. Injection site lesions in carcasses of cattle receiving injections at branding and weaning. Journal of Animal Science (1995) 73: 3235-3240.
COVEXIN®, TASVAX® and VISION® are registered trademarks of Intervet International B.V. Used under license.
MERCK® is a registered trademark of Merck Canada Inc.
© 2019 Intervet Canada Corp. All rights reserved.
962840 CA-BOV-190700003You can also read
